Biologics Emerging as Panacea in Arthritis Therapeutics Market
Global health data suggests that, the populace in North America and Europe are more conscious regarding arthritis, and actively partake in diagnosis than those residing in developing countries. Sensing the success rate of arthritis therapeutics, manufacturers are allocating high budgets to fuel their research & development activities, which ensures the future availability of blockbuster drugs.
The recent time is, however, witnessing a shifting paradigm of patients’ reliance from pharmaceutical products towards biologics, as biologic therapies are reported to bring dramatic improvements in patients’ quality of life. Furthermore, there are several biologic products in phase III clinical trials, which is indicative of strong commercial prospects for manufacturers in the arthritis therapeutics market.
Weighing the impact of key influencers, a recent report published by Fact.MR infers that, the arthritis therapeutics market is estimated to grow 1.5X during the forecast period (2020 - 2027).
For detailed insights on market taxonomy, request a sample copy of the report here.
Parenteral Qualifies as Default Route of Administration
According to the Fact.MR study, preference for the parenteral route of administration will be 83% more than the topical and oral routes combined in 2020, on account of the high precision of dosage offered by this route, which leads to better patient outcomes. Cost and recovery time, in turn, are turning out to be key determiners in the selection of route of administration. Following this, increased availability of biosimilar products at competitive rates through parenteral routes is projected to retain high preference for the injection of drugs during the forecast period.
On a relative note, patients’ proclivity for oral arthritis therapeutics is likely to remain moderate, as this route is preferred in cases wherein patients are required to follow a long-term course of medication. Additionally, the introduction of topical NSAIDs for the treatment of joint pains will offer low-to-moderate stimulus to the topical route of administration in the arthritis therapeutics market during the forecast period.
Steep Rise in Drug Prices to Take a Toll on Health of Arthritis Therapeutics Market
Advanced antibody therapeutics have been outperforming the sales of disease-modifying antirheumatic drugs (DMARD) in recent times, on account of their relatively high efficiency. However, better outcomes offered by these drugs comes at a price, a steep one indeed, which accommodates a range of US$ 1,000 to US$ 3,000 per month.
The price of the popular drug used for treatment of arthritis - Humira - increased by 100% from US$ 19,000 a year in 2012 to US$ 38,000 a year in 2018, as per data presented by SSR Health. This price rise is not limited to only Humira. Enbrel saw an 80% hike in its price since 2013, as reported by the Alliance of Community Health Plans. Given the long-term recommendation of these drugs to control arthritis, a perpetual increase in prices could shake the monthly budgets of patients, and, is hence, diverting their attention towards complementary and alternative therapies.
How can Manufacturers Offset Challenges Associated with High Cost of Drugs?
High penetration of smartphones in parallel to low-cost of operation of distribution network is promising the growth of online pharmacies as a key distribution channel. In the arthritis therapeutics market, where high cost concerns have been impeding sales prospects for players, targeting sales through online pharmacies can help offset the challenge through heavy deals and discounts offered by these channels. In 2020, online pharmacies are projected to drive sales tantamount to a value of US$ 3.5 Bn, and the trend of online shopping driven by convenience will strengthen sales in future.
Currently, retail pharmacies account for 79% of total sales in the arthritis therapeutics market, as large chains and strong distribution network coupled with 24X7 accessibility is gaining prominence to this distribution channel. It is recommended for players in the arthritis therapeutics market to increase distribution-oriented partnerships with key retail partners to amplify their sales.
For detailed regional analysis, request a sample copy of the report here.
North America’s Lead Fuelled by High Availability of Drugs
The arthritis therapeutics market is more concentrated in developed regions such as North America and Europe as compared to other parts of the world. Rigorous research & development initiatives undertaken by players concentrated in these regions are projected to diversify portfolios, strengthen the pipeline of drugs, and, in turn, boost the availability of drugs. Recent addition of biologic and biosimilar in the arthritis therapeutics list, on the backdrop of patent expiration of blockbuster drugs, is witnessed in these regions. In developing regions, increasing investments directed towards bringing progressive improvements in the healthcare industry are projected to promise strong growth for the arthritis therapeutics market in Asia Pacific. In developed countries of Asia Pacific, such as Japan, New Zealand, and Australia, the adoption of biologic drugs is anticipated to remain high during the forecast period.
Request research methodology of this report.
Arthritis Therapeutics Market - Scope of the Study
Fact.MR, in its exclusive research report on the arthritis therapeutics market, highlights actionable insights and winning imperatives for stakeholders. This comprehensive study unfolds rare and distinguished intelligence regarding impactful dynamics, which directly or indirectly influence the growth of the arthritis therapeutics market during the forecast period (2020 - 2027). With the help of crucial insights discussed in this study, stakeholders will gain a thorough idea regarding the growth trajectory of the arthritis therapeutics market.
This comprehensive study offers incisive data regarding the drivers, threats, restraints, and opportunities present in the arthritis therapeutics market. The study also recalibrates the impact of each of these dynamics to estimate the size of the arthritis therapeutics market for the given period. Authors of the report have taken ample care to measure and include the relevance and impact of microeconomic as well as macroeconomic factors that hold potential to influence the growth of the arthritis therapeutics market during the forecast period.
The global study offers crucial information about global, regional, and local players operating in the arthritis therapeutics market, along with their estimated market share. Market share has been estimated in terms of value (US$ Mn). Besides providing key information regarding the concentration of leading, prominent, and local players, the study also aims at equipping stakeholders with the best of information regarding winning strategies, recent developments, and financials.
Arthritis Therapeutics Market - Assessment of Key Segments
With an aim to offer granular level insights into the arthritis therapeutics market, authors of the report have segmented the landscape on the basis of type, drug class, route of administration, distribution channel, and region. This global research report also offers information regarding the incremental opportunity available in the arthritis therapeutics market during the forecast period. Key segments of the arthritis therapeutics market include:
|
Type |
Drug Class |
Route of Administration |
Distribution Channel |
Region |
|
Rheumatoid Arthritis |
TNF Inhibitors |
Oral |
Hospital Pharmacies |
North America |
|
Osteoarthritis |
Interleukin Inhibitors |
Parenteral |
Retail Pharmacies |
Europe |
|
Arthritis |
NSAIDS |
Topical |
Online Pharmacies |
Asia Pacific |
|
Gout |
Corticosteroids |
|
|
Latin America |
|
Others |
Xanthine Oxidase Inhibitors |
|
|
Middle East & Africa |
|
|
Others |
|
|
|
This detailed guide, based on the latest market movement, ensures that only precise information reaches stakeholders, so as to help them gain an upper hand over their competitors in the global arthritis therapeutics market. This exclusive guide offers crucial information about the current trends, pipeline drugs, unmet drugs, future scope, and government regulations for the arthritis therapeutics market.
Key players profiled in this comprehensive study on the arthritis therapeutics market include Sanofi, Novartis AG, F.Hoffmann-La Roche Ltd, Eli Lily and Company, Janssen Global Services, LLC, Amgen, Inc., AbbVie, Inc., Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, and Merck & Co., Inc.
Arthritis Therapeutics Market - Research Methodology
The research undertaken by seasoned analysts at Fact.MR consists of a systematic approach. A combination of the bottom-up and top-down approach is leveraged to estimate the size of the arthritis therapeutics market. Besides this, primary and secondary researches are carried out through credible sources to gain crucial insights into the arthritis therapeutics market. For conducting primary research, interviews and discussions were carried out with industry experts, key opinion leaders, vendors, and distributors.
Besides these, respondents also include CEOs, presidents, directors, chairmen, vice presidents, marketing managers, suppliers, distributors, and chief medical officers, among others. This helps in assessing the demand-supply gap prevailing in the arthritis therapeutics market. In order to conduct secondary research, marketing collaterals, company websites, industry associations, and government statistics were studied. In addition to this, reports as well as content pieces published by credible sources, such as company annual reports, investor presentations, and SEC-filings were studied.
Besides this, governmental and public portals, such as World Health Organization (WHO), OECD, FDA, Centres of Disease Control and Prevention (CDC), the Centres for Medicare & Medicaid Services, MoHFW, Government of India, Dermatology News, Arthritis Foundation, National Psoriasis Foundation, Arthritis Foundation, Psoriasis Association, European Societies of Dermatology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Centre for Complementary and Integrative Health were referred to, in order to gain crucial information regarding key players in the arthritis therapeutics market. Insights obtained through primary and secondary research are then authenticated with the data triangulation method.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Arthritis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Arthritis Therapeutics Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key product/brand Analysis
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. Regulatory Scenario by Region/globally
6. Global Arthritis Therapeutics Market Analysis and Forecast, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
6.3.1. Rheumatoid Arthritis
6.3.2. Osteoarthritis
6.3.3. Psoriatic Arthritis
6.3.4. Gout
6.3.5. Others
6.4. Market Attractiveness By Type
7. Global Arthritis Therapeutics Market Analysis and Forecast, By Drug Class
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
7.3.1. TNF Inhibitors
7.3.2. Interleukin Inhibitors
7.3.3. NSAIDs
7.3.4. Corticosteroids
7.3.5. Xanthine Oxidase Inhibitors
7.3.6. Others
7.4. Market Attractiveness By Drug Class
8. Global Arthritis Therapeutics Market Analysis and Forecast, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Topical
8.4. Market Attractiveness By Route of Administration
9. Global Arthritis Therapeutics Market Analysis and Forecast, By Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness By Distribution Channel
10. Global Arthritis Therapeutics Market Analysis and Forecast, By Region
10.1. Key Findings
10.2. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Sub-region /Region
11. North America Arthritis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
11.2.1. Rheumatoid Arthritis
11.2.2. Osteoarthritis
11.2.3. Psoriatic Arthritis
11.2.4. Gout
11.2.5. Others
11.3. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
11.3.1. TNF Inhibitors
11.3.2. Interleukin Inhibitors
11.3.3. NSAIDs
11.3.4. Corticosteroids
11.3.5. Xanthine Oxidase Inhibitors
11.3.6. Others
11.4. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Topical
11.5. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.6.1. U.S.
11.6.2. Canada
11.7. North America Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Drug Class
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country/Sub-region
12. Europe Arthritis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
12.2.1. Rheumatoid Arthritis
12.2.2. Osteoarthritis
12.2.3. Psoriatic Arthritis
12.2.4. Gout
12.2.5. Others
12.3. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
12.3.1. TNF Inhibitors
12.3.2. Interleukin Inhibitors
12.3.3. NSAIDs
12.3.4. Corticosteroids
12.3.5. Xanthine Oxidase Inhibitors
12.3.6. Others
12.4. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Topical
12.5. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Drug Class
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Arthritis Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
13.2.1. Rheumatoid Arthritis
13.2.2. Osteoarthritis
13.2.3. Psoriatic Arthritis
13.2.4. Gout
13.2.5. Others
13.3. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
13.3.1. TNF Inhibitors
13.3.2. Interleukin Inhibitors
13.3.3. NSAIDs
13.3.4. Corticosteroids
13.3.5. Xanthine Oxidase Inhibitors
13.3.6. Others
13.4. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Topical
13.5. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region /Sub-region, 2017–2027
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Drug Class
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Arthritis Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
14.2.1. Rheumatoid Arthritis
14.2.2. Osteoarthritis
14.2.3. Psoriatic Arthritis
14.2.4. Gout
14.2.5. Others
14.3. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
14.3.1. TNF Inhibitors
14.3.2. Interleukin Inhibitors
14.3.3. NSAIDs
14.3.4. Corticosteroids
14.3.5. Xanthine Oxidase Inhibitors
14.3.6. Others
14.4. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Topical
14.5. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region /Sub-region, 2017–2027
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Drug Class
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Arthritis Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027
15.2.1. Rheumatoid Arthritis
15.2.2. Osteoarthritis
15.2.3. Psoriatic Arthritis
15.2.4. Gout
15.2.5. Others
15.3. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
15.3.1. TNF Inhibitors
15.3.2. Interleukin Inhibitors
15.3.3. NSAIDs
15.3.4. Corticosteroids
15.3.5. Xanthine Oxidase Inhibitors
15.3.6. Others
15.4. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
15.4.1. Oral
15.4.2. Parenteral
15.4.3. Topical
15.5. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region , 2017–2027
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Market Attractiveness Analysis
15.7.1. By Type
15.7.2. By Drug Class
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Share Analysis By Company (2018)
16.2. Company Profiles
16.2.1. Novartis AG
16.2.2. Eli Lilly and Company
16.2.3. Amgen, Inc.
16.2.4. Merck & Co., Inc.
16.2.5. Bristol-Myers Squibb Company
16.2.6. Pfizer, Inc.
16.2.7. AbbVie, Inc.
16.2.8. Janssen Global Services, LLC (Johnson & Johnson)
16.2.9. F. Hoffmann-La Roche Ltd
16.2.10. Sanofi
Fact.MR offers custom research services that help clients to get specific research solutions
Related reports
We are committed towards customer satisfaction and quality service.
Our Clients
Arthritis Therapeutics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2027